Clinical Trial Search

Phase 3 N=645 A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Arthritis, Rheumatoid

Primary: Number of Patients With Adverse Events as a Measure of Safety Per Treatment Group in Period I — 0; 0; 1; 1 participants

Fujifilm Kyowa Kirin Biologics Co., Ltd. Results Mar 2019 6.1% serious AE View details

Phase 3 N=32 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Hereditary Angioedema (HAE)

Primary: Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant — 0.42; 0.55; 0.57 Hour (h)

Shire Results Mar 2019 0.0% serious AE View details

Phase 3 N=162 Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General

Primary: Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9 — 2.53; 2.92; 3.93 Minutes

Merck Sharp & Dohme LLC Results Mar 2019 10.0% serious AE View details

Phase 3 N=65 A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Uterine Fibroids

Primary: Percentage of Participants With a Maximum NRS Score of 1 or Less During the 28 Days Before the Final Dose of Study Drug — 57.6; 3.1 percentage of participants — p=<0.0001

Takeda Results Mar 2019 0.0% serious AE View details

Phase 3 N=281 A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Uterine Fibroids

Primary: Percentage of Participants With Total PBAC Score of <10 From Week 6 to 12 — 82.2; 83.1 percentage of participants — p=0.0013

Takeda Results Mar 2019 0.7% serious AE View details

Phase 3 N=228 A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat

Sore Throat

Primary: Percentage of Participants Without Sore Throat According to TSS Score — 84.35; 73.21; 13.91; 17.86 percentage of participants — p=0.028

Sandoz Results Mar 2019 0.0% serious AE View details

Phase 3 N=1,346 12-Week Study of Plecanatide for CIC (The CIC3 Study)

Chronic Idiopathic Constipation

Primary: Number of Durable Overall CSBM Responders , Mean Replacement Approach — 46; 95; 86 Participants

Bausch Health Americas, Inc. Results Mar 2019 1.1% serious AE View details

Phase 3 N=655 Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Bacterial Infections · Skin Structures and Soft Tissue Infections

Primary: Number of Participants With Early Clinical Response — 268; 266; 23; 19 Participants

Paratek Pharmaceuticals Inc Results Mar 2019 3.1% serious AE View details

Phase 3 N=229 Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat

Sore Throat

Primary: Percentage of Patients Without Sore Throat According to the Tonsillopharyngitis Severity Score (TSS) — 89.47; 75.65; 7.02; 19.13 Percentage of Participants — p=0.00001

Sandoz Results Mar 2019 0.0% serious AE View details

Phase 3 N=51 Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

Reduction in Heavy Drinking in Patients With HIV

Primary: HAART Adherence — 7; 4; 6; 4 Participants

Yale University Results Mar 2019 17.7% serious AE View details

Phase 3 N=197 ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Primary: Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183 — -0.82; 8.39 percent change

Alexion Pharmaceuticals, Inc. Results Mar 2019 18.4% serious AE View details

Phase 3 N=254 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

GVHD · Adult Acute Myeloid Leukemia · Adult Acute Lymphoid Leukemia

Primary: Number of Participants With First Occurrence of Moderate to Severe Chronic GVHD According to 2005 NIH Criteria as Determined by the Independent Endpoint Committee or…

Neovii Biotech Results Mar 2019 74.0% serious AE View details

Phase 3 N=292 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Ulcerative Colitis

Primary: Percentage of Participants With a Clinical Response at Week 10 in Induction Phase — 32.9; 39.6 percentage of participants — p=0.2722

Takeda Results Mar 2019 11.5% serious AE View details

Phase 3 N=130 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.0 percentage of participants — p=0.009

Gilead Sciences Results Mar 2019 0.8% serious AE View details

Phase 3 N=20 A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

COPD

Primary: Specific Airway Volume (siVaw) — 1.79; 1.02 mL/L — p=<0.0001

Pearl Therapeutics, Inc. Results Mar 2019 6.8% serious AE View details